Immunological Implications in Neuromuscular Disorders

Guest Editors:

Dr. Filippo Brighina
Department of Biomedicine, Neuroscience and advanced Diagnostics (BIND), University of Palermo, Via del Vespro 143, 90129 Palermo, Italy

Dr. Vincenzo Di Stefano
Department of Biomedicine, Neuroscience and advanced Diagnostics (BIND), University of Palermo, Via del Vespro 143, 90129 Palermo, Italy

Deadline for manuscript submissions:
closed (5 December 2023)

Message from the Guest Editors

In the last fifty years, our knowledge has rapidly grown on immunology and immunological aspects of neuromuscular disorders. Indeed, available antibody tests for many autoimmune conditions have driven growing interest in autoimmunity, as well as the possibility to effectively treat patients affected by the autoimmune disease through new developed and emerging target therapies (i.e., Rituximab, Eculizumab, etc.) for the treatment of Myasthenia Gravis and Chronic inflammatory Demyelinating Polyradiculoneuropathy. On the other side, the description of an immunological basis with specific diagnostic antibody testing for relevant conditions such as "Stiff person syndrome", "Isaacs syndrome" and other "paraneoplastic syndromes", might have contributed to this revolution.

Papers on targets therapies (Rituximab, Eculizumab, other monoclonal antibodies for autoimmune neuromuscular disorders) or Immune Checkpoint Inhibitors in malignances are welcome.

mdpi.com/si/109265

Special Issue

Editor-in-Chief

Prof. Dr. Stephen D. Meriney
Department of Neuroscience,
University of Pittsburgh,
Pittsburgh, PA 15260, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, CAPlus / SciFinder, and other databases.
Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2023).

Contact Us